Compare Schwab US Large Cap Growth ETF (SCHG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Schwab US Large Cap Growth ETF trades at $35.02, while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). Which is the better fit depends on your goals.
| SCHG | VRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $35.94 | $557.96 |
52-Week Low | $28.10 | $376.62 |
Market Cap | — | $134.06B |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $35.25, down 0.79% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest and offers exposure to large-cap growth stocks at a competitive expense ratio. Recent news highlights SCHG's historical outperformance versus the S&P 500 and ongoing comparisons with peers like QQQM and VUG.
Long-term growth potential remains supported by SCHG's track record, though concentration risk in top holdings and market volatility pose challenges. The ETF's low-cost structure and growth focus present opportunities for investors seeking diversified large-cap exposure, but requires monitoring of valuation levels and sector rotations.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
